News
Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.
The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.
The VISTA trial is evaluating and comparing 2 dose levels of laru-zova to an untreated control group for the treatment of X-linked retinitis pigmentosa (XLRP).
Clinical research sites face challenges in managing the growing complexity of trials. The increasing administrative burden, protocol complexities, constant staff turnover, and operational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results